Project Grant R44CA224460

This $399,970 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of DUO-207, an innovative nanomedicine to improve treatment for pancreatic cancer. DUO-207 is a fixed-dose combination therapy that delivers gemcitabine and paclitaxel in a 14nm nanoparticle designed to overcome delivery challenges of prior nanomedicines. Key innovations include a patent-pending polymer that protects gemcitabine from rapid...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $677,176 to The Research Foundation For The State University Of New York to develop an innovative interstitial chemophototherapy (I-CPT) treatment approach for locally advanced pancreatic cancer. The key products and services to be delivered include: Defining optimal light dosimetry for I-CPT in preclinical pancreatic cancer models, including patient-derived xenograft and orthotopic...

This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $703,540 to Brigham & Women's Hospital Inc. to validate the performance of their implantable microdevice (IMD) technology in predicting treatment response for patients with head and neck squamous cell carcinoma. The IMD releases spatially confined microdoses of up to 20 drugs into the tumor and measures the response to each treatment, enabling the...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $654,681 to Case Western Reserve University (CWRU) to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The key objectives are to 1) design and develop multifunctional ionizable ELNP-based peptide vaccines for effective PDAC...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to advance the targeted delivery of stromal-targeting therapies for pancreatic ductal adenocarcinoma (PDAC). The $599,474 award, effective September 1, 2024 through August 31, 2029, will support the development of a local controlled-release platform for intratumoral delivery of hyaluronidase. This approach is intended to reduce the dense tumor desmoplasia that acts as a physical...

This Project Grant award of $269,280 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the Translational Genomics Research Institute (TGen) to develop a new therapeutic targeting cellular senescence in pancreatic cancer. The project aims to determine the biological effects of a senescent cell-targeted antibody, SIWA318, and evaluate its ability to enhance the efficacy of standard chemotherapy or immune checkpoint inhibitors in preclinical...

This SBIR Phase I grant, awarded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), provides $400,000 to Canget Biotekpharma LLC to perform critical pre-clinical studies and regulatory filings to enable first-in-human clinical trials of their novel cancer drug candidate FL118 for advanced pancreatic cancer. Specifically, the project aims to: (1) conduct non-GLP and GLP toxicology and toxicokinetic studies of the clinically compatible FL118 formulation; and (2) author and...

The National Cancer Institute awarded Oncotrap Inc. a $400,000 Project Grant to develop an aptamer-directed IgG1-Fc drug conjugate (AFDC) platform for the treatment of pancreatic ductal adenocarcinoma (PDAC). The project aims to validate the ability of the APTPDAC aptamer to selectively kill PDAC cells and create a potent AFDC targeting PDAC cells. Additionally, the project will evaluate the in vivo anti-tumor efficacy of the AFDC in PDAC mouse models and identify the target cell surface...

This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Oncoblaze LLC to develop a novel medical device for targeted chemotherapy delivery to treat cancer tumor recurrence. The project aims to create a device prototype that uses an infrared laser to precisely heat and trigger the release of chemotherapy drugs in the tissue surrounding a surgically removed tumor. The device will also...

This federal Project Grant award of $338,828, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports innovative research to investigate the use of a novel platinum-based anticancer drug called Triplatin for the treatment of pancreatic cancer. The key focus of this research is to explore how the tumor-specific expression of glycosaminoglycans (GAGs), particularly chondroitin-4-sulfate (C4S), can be leveraged to enhance the tumor delivery...